ATAI Life Sciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Walsh from JonesTrading reiterated a Buy rating on the stock and has a $16.00 price target.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Justin Walsh has given his Buy rating due to a combination of factors related to ATAI Life Sciences’ advancing clinical pipeline and market opportunity. He highlights that ATAI is positioned for a data-rich 2026, with pivotal Phase II results expected from all three of its clinical-stage programs, which could substantially de-risk the story. In particular, he views lead compounds BPL-003 and VLS-01 as well suited for treatment-resistant depression because their short duration of action supports a clinic-based model similar to the commercial framework established by esketamine, in a large and under-served patient population where multiple successful therapies can coexist.
Walsh also underscores that recent Phase IIb data for BPL-003 in treatment-resistant depression showed rapid and durable symptom improvement versus both baseline and a low-dose comparator, and that a second administration extended benefits further, reinforcing the drug’s therapeutic potential. He notes planned regulatory interactions, including an End-of-Phase II meeting with the FDA that, if favorable, could enable a Phase III trial to start in 2Q26. Additionally, he points to further planned studies of BPL-003, continued development of the EMP-01 program in social anxiety disorder, and a solid cash position as factors that support ATAI’s ability to execute on its pipeline, collectively justifying the reiterated Buy rating and $16 price target.
In another report released on January 8, Needham also maintained a Buy rating on the stock with a $12.00 price target.